140 filings
Page 3 of 7
8-K
tdddc645xydmxe wc69
18 Dec 20
FibroGen Provides Regulatory Update on Roxadustat
5:10pm
8-K
pt1j65
1 Dec 20
Departure of Directors or Certain Officers
8:05am
8-K
udbbnm8r kd9
12 Nov 20
Entry into a Material Definitive Agreement
4:45pm
8-K
zf2tz5bk0
5 Nov 20
FibroGen Reports THIRD Quarter 2020 Financial Results
4:05pm
8-K
bnki vp2qohb8m96
6 Aug 20
FibroGen Reports SECOND Quarter 2020 Financial Results
4:10pm
8-K
76jqe07x9v1q3 ijj6
6 Aug 20
FibroGen Announces New Appointments to its Board of Directors
4:06pm
8-K
naflh0mp
10 Jul 20
Entry into a Material Definitive Agreement
5:00pm
8-K
alg81mfc1i vke
23 Jun 20
Departure of Directors or Certain Officers
4:59pm
8-K
aw4y13n pcio
9 Jun 20
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
8kl lwv18dr
7 May 20
FibroGen Reports First Quarter 2020 Financial Results
4:09pm
8-K
ixbx2 lez
24 Mar 20
Master Supply Agreement
5:24pm
8-K
x70s8g2h
2 Mar 20
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
4:06pm
8-K
yva2dfrfza j1ttf
13 Feb 20
Departure of Directors or Certain Officers
4:05pm
8-K
wx5yj0wj1
11 Feb 20
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease
5:16pm
8-K
xfpdm1z
30 Jan 20
Astellas Submits Supplemental New Drug Application for Approval of
4:40pm
8-K
8d0gd963e7
13 Jan 20
Regulation FD Disclosure
9:01am
8-K
lr8k7 ib4f
6 Jan 20
Fibrogen Names Enrique Conterno As Chief Executive Officer
5:23pm
8-K
59dn hruf
23 Dec 19
Fibrogen Submits New Drug Application to the U.S. Fda for Roxadustat In Patients with Anemia of Chronic Kidney Disease
9:06am
8-K
erlf9l
16 Dec 19
Departure of Directors or Certain Officers
12:00am
8-K
1tsus7
2 Dec 19
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
7:10am